Majority of Italian Parents Appropriately Hesitant on Childhood COVID-19 Vaccination

By Peter A. McCullough, MD, MPH

The peer-reviewed medical literature on COVID-19 is under strong bias from the editors and publishers to allow mainly favorable papers into publication on COVID-19 vaccination. A proxy on medical establishment vaccination sentiment are papers that report fair balanced survey results from either patients or parents of children contemplating COVID-19 vaccination. After two years of relentless promotion from global and country public health authorities, reports of the majority not wanting COVID-19 vaccination for their children should be taken as serious “push back.”

Bianchi et al, conducted a meta-analysis of nine Italian studies spanning November, 2020 to March, 2022. The overall rate of appropriate vaccine hesitancy was 55%. Younger and unvaccinated parents were stronger predictors of protecting their children from vaccination. Belief that the vaccines were either unsafe, ineffective, or not medically necessary were the most common justification for vaccine hesitancy.

Bianchi FP, Stefanizzi P, Cuscianna E, Riformato G, Di Lorenzo A, Giordano P, Germinario CA, Tafuri S. COVID-19 vaccination hesitancy among Italian parents: A systematic review and meta-analysis. Hum Vaccin Immunother. 2023 Jan 25:2171185. doi: 10.1080/21645515.2023.2171185. Epub ahead of print. PMID: 36698309.

These data support rational parental decision making on declining COVID-19 vaccination in children. As more countries withdraw mandates for vaccines and remove younger individuals from eligibility, these trends could be expected to strengthen over time.

This study should be considered in light of California’s recent decision to drop school vaccine mandates. The data suggest parents are becoming more discerning as countries and states fail to make a compelling case that COVID-19 is safe, effective, or needed for any reason at this stage of the pandemic.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

TrialSite News Feb 6, 2023 California ‘Quietly’ Drops Student COVID-19 Vaccine Mandate

Bianchi FP, Stefanizzi P, Cuscianna E, Riformato G, Di Lorenzo A, Giordano P, Germinario CA, Tafuri S. COVID-19 vaccination hesitancy among Italian parents: A systematic review and meta-analysis. Hum Vaccin Immunother. 2023 Jan 25:2171185. doi: 10.1080/21645515.2023.2171185. Epub ahead of print. PMID: 36698309.

Hyperbaric Oxygen for Treatment of Long COVID-19 Syndrome (HOT-LoCO)

By Peter A. McCullough, MD, MPH

Many followers have been clamoring for some approach to post-COVID-19 syndromes. I have tried many therapies in clinical practice and have been disappointed with my observations. Approximately 50% of patients hospitalized with severe respiratory COVID-19 suffer from post-COVID-19 syndromes including weakness, depression, muscle fatigue and loss of mass, hair loss, sleep disturbance, anosmia, tinnitus, headaches, and general inanition. The observational studies suggest these symptoms are transient and will resolve over time. However, patients are suffering now and want a pathway to prompt recovery. Several observational studies and one small randomized trial demonstrated salutary effects of hyperbaric oxygen therapy (HBOT) consisting of a series of treatments with the whole body in a HBOT chamber where the partial pressure of oxygen is modified to levels used to treat chronic wounds and other medical problems.

Zilberman‑Itskovich et al randomized 73 post-COVID syndrome patients to a very intense protocol of 40 daily sessions, five sessions per week within a two-month period. The HBOT procedure included breathing 100% oxygen by mask at 2ATA for 90 min with five-minute breaks every 20 min. Compression/decompression rates were 1.0 m/min. The results on brain imaging and quality of life were impressive, however, I doubt this would be practical in the real world.

Kjellberg and coworkers published the more practical HOT-LoCO clinical trial protocol which outlines the inclusion and exclusion criteria and the HBOT treatment schedule of 10 treatments over 6 weeks. As with acute COVID-19 therapies, it would be optimal if all patients could be in a randomized trial. However, many locations will have no access to clinical trials, thus the publication a protocol gives a standardized approach that other physicians and patients can review and if attempted, could be carried out in such a manner to be generalizable to the trial results when they become available in a few years.

Kjellberg A, Abdel-Halim L, Hassler A, El Gharbi S, Al-Ezerjawi S, Boström E, Sundberg CJ, Pernow J, Medson K, Kowalski JH, Rodriguez-Wallberg KA, Zheng X, Catrina S, Runold M, Ståhlberg M, Bruchfeld J, Nygren-Bonnier M, Lindholm P. Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open. 2022 Nov 2;12(11):e061870. doi: 10.1136/bmjopen-2022-061870. PMID: 36323462; PMCID: PMC9638753.

In general HBOT is safe, however the main drawback is cost. In the US, the cost of hyperbaric oxygen therapy per individual treatment for patients can vary between more than $100 at a HBOT clinic, to more than a $1,000 for at a large medical center. In my practice, HBOT is the only form of treatment I have found in post COVID-19 syndromes (especially residual pulmonary disease) that appears to have a bone fide treatment effect. My observations await corroboration by large, definitive randomized trials.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

Zilberman-Itskovich, S., Catalogna, M., Sasson, E. et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep 12, 11252 (2022). https://doi.org/10.1038/s41598-022-15565-0

Kjellberg A, Abdel-Halim L, Hassler A, El Gharbi S, Al-Ezerjawi S, Boström E, Sundberg CJ, Pernow J, Medson K, Kowalski JH, Rodriguez-Wallberg KA, Zheng X, Catrina S, Runold M, Ståhlberg M, Bruchfeld J, Nygren-Bonnier M, Lindholm P. Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open. 2022 Nov 2;12(11):e061870. doi: 10.1136/bmjopen-2022-061870. PMID: 36323462; PMCID: PMC9638753.

Varicella-Zoster Reactivation after COVID-19 Illness versus SARS-CoV-2 Vaccination

By Peter A. McCullough, MD, MPH

Many papers in the medical literature seem to pit a consequence such as myocarditis or stroke as either occurring as a consequence of COVID-19 illness compared with COVID-19 vaccination. Because the denominator is so large for acutely ill hospitalized patients with COVID-19 especially during the first two years of the pandemic allowing ICD code capture of comorbidities, authors erroneously conclude the illness is “more dangerous” or a “bigger risk factor.” These arguments are daft in my opinion since COVID-19 respiratory illness is treatable and a recent paper from Klaassen et al has estimated 94% are already recovered from COVID-19—so it is water under the bridge. Not true for COVID-19 vaccines which are still mandated by some ill-advised schools, employers, and agencies. One way of looking for what is a more pressing and continued problem is to survey the medical literature.

Martinez-Reviejo et al completed a literature review of varicella-zoster reactivation (shingles) and compared cases arising after vaccination and those with the respiratory infection. There were more manuscripts and cases after vaccination. However, the manifestations of varicella-zoster were more severe in those with acute COVID-19 illness which was also high in disease severity.

Martinez-Reviejo R, Tejada S, Adebanjo GAR, Chello C, Machado MC, Parisella FR, Campins M, Tammaro A, Rello J. Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights. Eur J Intern Med. 2022 Oct;104:73-79. doi: 10.1016/j.ejim.2022.07.022. Epub 2022 Aug 1. PMID: 35931613; PMCID: PMC9340059.

I found it curious the authors did not disclose the shingles vaccine status in the tables. The bottom line is that shingles can occur with severe COVID-19 and it is treatable. Acute COVID-19, however is amenable to early therapeutics so severe cases can be avoided and most of us have recovered SARS-CoV-2 infection. COVID-19 vaccination continues to be an ongoing threat for varicella-zoster reactivation syndromes, some of which are very serious including ocular damage and long-lasting painful cutaneous syndromes.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA. Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022. medRxiv [Preprint]. 2022 Nov 23:2022.11.19.22282525. doi: 10.1101/2022.11.19.22282525. PMID: 36451882; PMCID: PMC9709792.

Martinez-Reviejo R, Tejada S, Adebanjo GAR, Chello C, Machado MC, Parisella FR, Campins M, Tammaro A, Rello J. Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights. Eur J Intern Med. 2022 Oct;104:73-79. doi: 10.1016/j.ejim.2022.07.022. Epub 2022 Aug 1. PMID: 35931613; PMCID: PMC9340059.

Jordan Peterson’s Proposal for Alternative to World Economic Forum

By JOHN LEAKE

In his recent Joe Rogan interview, Dr. Jordan Peterson articulated a vision of an alternative to the central, oligarchic power that has, in recent years, greatly extended its power over mankind. As he said to Mr. Rogan:

You guys [Russell Brand and Joe Rogan] are very sensitive to the danger of that kind of corrupt collusion, that regulatory capture that occurs when corporate entities, media entities, and governmental entities are all in bed together—like the FDA, the CDC, and so forth and so on.

For years, Dr. Peterson has been the world’s most eloquent critic of corrupt central power. As he has frequently explained, much of the trouble is the inevitable outcome of an organization or jurisdiction that becomes so big that those who occupy the command center cease having any contact with or understanding of the far flung communities that lie in their dominion.

His critique touches on the longstanding tension between Empire and Nation State. In the U.S. American context, we see the same tension between Federal Authority and States Rights. It seems to me that one arrangement is not necessarily better than the other—it all depends on the quality of the laws, the integrity of their administration, and the character of those in office. I write this post in a hotel a few hundred yards away from the Secretariat Building in New Delhi, India—the administrative seat of the British rule in India from 1931-1947, now the government cabinet offices of the Republic of India. There is a vast literature on British rule in India, and whether it was (on the whole) good or bad for the diverse peoples who occupy the Indian subcontinent. Some have argued that British rule brought many positive developments to the region; others have argued that British rule was exploitative. I suspect it was a combination of both.

In the case of the COVID-19 pandemic response, it’s clear that the Centralized Power/Imperialist model was a catastrophe. Countless observers were astonished at the “Lock Step” response of the U.S., UK, Canada, EU, and Australian governments to the Pandemic—a scenario envisaged by a Rockefeller Foundation’s 2010 global governance strategy document Scenarios for the Future of Technology and International Development.

This is no coincidence, because the Rockefeller Foundation, the Bill and Melinda Gates Foundation, the World Economic Forum, and the Wellcome Trust are key players in what we call the Bio-Pharmaceutical Complex—a centralized, globalist power structure that drove the pandemic response.

Prior to 2020, it was not in the least bit controversial to point out that the Rockefeller and Gates Foundations were wielding an outsize influence on global health and agricultural policy. Indeed, in 2016, the Global Policy Forum published a major study on this state of affairs. Far from characterizing this study as a “conspiracy theory,” the UK Guardian published a long report on it.

I’m very glad to see that Dr. Peterson is now speaking about the “regulatory capture that occurs when corporate entities, media entities, and governmental entities are all in bed together—like the FDA, the CDC.” To see this section of his recent Joe Rogan interview, CLICK the image below.

CDC Reports Hundreds of Guillain-Barre Cases with mRNA COVID-19 Vaccination

By Peter A. McCullough, MD, MPH

One of the early product warnings came in July 2021 with COVID-19 vaccination was Guillain-Barre Syndrome (GBS) or life-threatening ascending paralysis with the Janssen adenoviral COVID-19 vaccine. Using VAERS, Abara et al reported 211 cases of GBS submitted from December 2020 through January 2022 occurred with mRNA vaccines (Pfizer, Moderna) presenting with symptoms 8-10 days after taking the shot.

Abara WE, Gee J, Marquez P, Woo J, Myers TR, DeSantis A, Baumblatt JAG, Woo EJ, Thompson D, Nair N, Su JR, Shimabukuro TT, Shay DK. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. JAMA Netw Open. 2023 Feb 1;6(2):e2253845. doi: 10.1001/jamanetworkopen.2022.53845. PMID: 36723942.

Of note, only 16% of cases reported by the patients themselves to the CDC leaving the majority to be reported by healthcare workers or the vaccine companies. The mean age was 59 years and sadly, 10 patients died after developing GBS. All but one of these cases died on the mechanical ventilator suggesting the systemic syndrome was far more lethal than GBS survived in other conditions (West Nile virus, Campylobacter jejuni, influenza vaccine etc.) These data strongly support FDA warnings for GBS in the FAQ for EUA vaccination and in all consent forms. This illness is a disaster for so many patients causing severe short and sometimes long term disability.

These findings are a severe blow to the mRNA vaccine development programs active in several companies including Moderna who recently received FDA Breakthrough Therapy Designation for their investigational respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345, in adults aged 60 years or older. Data safety monitoring boards and advisory committees should be on a alert for GBS which can occur days to weeks after injection with mRNA.

This paper illustrates several points: 1) the CDC believes VAERS is a solid database for research and is using it, 2) the majority of serious events like GBS are reported by healthcare providers and vaccine manufactures, not the patients or families, 3) the FDA/CDC are not updating EUA FAQ or consent documents, thus Americans are not getting fair informed consent with COVID-19 vaccination, 4) GBS is likely to occur to occur with mRNA and should be tagged as a special adverse event of interest in mRNA development programs.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

Abara WE, Gee J, Marquez P, Woo J, Myers TR, DeSantis A, Baumblatt JAG, Woo EJ, Thompson D, Nair N, Su JR, Shimabukuro TT, Shay DK. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. JAMA Netw Open. 2023 Feb 1;6(2):e2253845. doi: 10.1001/jamanetworkopen.2022.53845. PMID: 36723942.

FDA Grants Breakthrough Therapy Designation to Moderna for Investigational RSV Vaccine Feb 2, 2023 Aislinn Antrim, Editor

IgA Vasculitis after COVID-19 Vaccination

By Peter A. McCullough, MD, MPH

The human body makes thousands of normal proteins recognized to be our own by the immune system. These proteins maintain housekeeping of the cells, build up structures like muscle, and breakdown other proteins such as digestive enzymes. The beautiful system can go awry when the body recognizes an internal produced protein that is foreign. This is the disastrous result of blunderous groupthink by mRNA “inventors” who conceived of using RNA coding for an abnormal protein to be inserted in the body letting our own cells produce it and then brace for the auto-immune attack.

There are many classes of antibodies and our particular attention with respect to respiratory pathogens is with IgA found in secretions protecting the nasopharynx and urogenital tract. When IgA is aberrantly produced and circulatory in the human body it can attack the lining of blood vessel cells, skin, lungs, and kidneys.

Ramdani, from Tours, France, reported on 12 cases of COVID-19 vaccine induced IgA vasculitis confirmed by skin biopsy with an array of manifestations including kidney damage. The clinical clue was the vasculitic skin rash. I was shocked to read that several patients pushed their luck with boosters potentially provoking even more severe organ injury. All the patients received treatment and relapses were infrequent.

Ramdani Y, Bettuzzi T, Bouznad A, Delaitre L, Nassarmadji K, Didier K, Paul C, Liozon E, Tieu A, Richard-Colmant G, Terrier B, Moulis G, Lafaurie M, Pillebout E, Maillot F, Audemard-Verger A. IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients. J Rheumatol. 2023 Feb;50(2):252-257. doi: 10.3899/jrheum.220545. Epub 2022 Nov 1. PMID: 36319000.

The major points of this paper are: 1) auto-immune disease will happen after genetic vaccinations of any type and IgA vasculitis is just the tip of the iceberg, 2) skin rashes can be the only clue to internal organ damage and the need for treatment.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

Ramdani Y, Bettuzzi T, Bouznad A, Delaitre L, Nassarmadji K, Didier K, Paul C, Liozon E, Tieu A, Richard-Colmant G, Terrier B, Moulis G, Lafaurie M, Pillebout E, Maillot F, Audemard-Verger A. IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients. J Rheumatol. 2023 Feb;50(2):252-257. doi: 10.3899/jrheum.220545. Epub 2022 Nov 1. PMID: 36319000.